Abstract
This study aimed to compare primary care (PC) and infectious diseases (ID) provider adherence to HIV pre-exposure prophylaxis (PrEP) prescribing and monitoring parameters outlined in Centers for Disease Control/Department of Health and Human Services (CDC/DHHS) guidelines. This retrospective cohort analysis from 2017 to 2022 used prescription and laboratory order data to identify patients prescribed PrEP by PC or ID providers. Primary endpoints assessed were adherence to baseline and follow-up HIV monitoring recommendations in the 12 months following the initial PrEP prescription. Secondary endpoints included appropriate PrEP prescription order quantities (≤ 90-day supply), appropriate renal function monitoring, and identification of factors independently associated with follow-up HIV monitoring adherence. Of the 324 eligible patients identified, 112 received PrEP from an ID specialist and 212 from a PC provider. Patients prescribed PrEP from an ID specialist were more likely to have appropriately completed baseline HIV monitoring (OR = 2.56, 95% CI 1.20, 5.47), follow-up HIV monitoring (OR = 1.81, 95% CI 1.08, 3.05), and renal function monitoring (OR = 2.81, 95% CI 1.69, 4.68); The ID group was also more likely to have PrEP prescriptions appropriately authorized for a days’ supply of ≤ 90 days (OR = 4.41, 95% CI 2.60, 7.48). Patients receiving PrEP care from ID specialists had better adherence to all assessed PrEP prescribing and monitoring recommendations compared to those receiving care from PC providers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data and Code Availability
Relevant documentation, data, or code needed to support the validity of this study’s findings are available from the corresponding author upon reasonable request.
References
Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. In: Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html#anchor_1562942347. Accessed 21 Mar 2023.
PrEP for HIV prevention in the U.S. 2021. In: Centers for Disease Control and Prevention. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html. Accessed 21 Mar 2023.
Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015;53(4):293–301. https://doi.org/10.1097/mlr.0000000000000308.
Zhu W, Huang YA, Kourtis AP, Hoover KW. Trends in the number and characteristics of HIV pre-exposure prophylaxis providers in the United States, 2014–2019. J Acquir Immune Defic Syndr. 2021;88(3):282–89. https://doi.org/10.1097/qai.0000000000002774.
Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 Update: Clinical Providers’ Supplement. In: Centers for Disease Control and Prevention. 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-provider-supplement-2017.pdf. Accessed 21 Mar 2023.
Spinelli MA, Scott HM, Vittinghoff E, et al. Provider adherence to pre-exposure prophylaxis monitoring guidelines in a large primary care network. Open Forum Infect Dis. 2018;5(6):1–4. https://doi.org/10.1093/ofid/ofy099.
New CDC Vital Signs Report reveals a decade of continuing HIV inequities on eve of world AIDS Day. Centers for Disease Control and Prevention. 2021. https://www.cdc.gov/nchhstp/newsroom/2021/2021-hiv-vital-signs-press-statement.html. Accessed 21 Mar 2023.
Saberi P, Berrean B, Thomas S, Gandhi M, Scott H. A simple pre-exposure prophylaxis (PrEP) optimization intervention for Health Care Providers Prescribing PrEP: pilot study. JMIR Form Res. 2018;2(1). https://doi.org/10.2196/formative.8623.
Carter MR, Aaron E, Nassau T, Brady KA. Knowledge, attitudes, and PrEP prescribing practices of health care providers in Philadelphia, PA. J Prim Care Community Health. 2019. https://doi.org/10.1177/2150132719878526.
Clement ME, Seidelman J, Wu J, et al. An educational initiative in response to identified PrEP prescribing needs among PCPs in the Southern U.S. AIDS Care. 2017;30(5):650–55. https://doi.org/10.1080/09540121.2017.1384534.
Storholm ED, Ober AJ, Mizel ML, et al. Primary care providers’ knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis (PrEP): informing network-based interventions. AIDS Educ Prev. 2021;33(4):325–44. https://doi.org/10.1521/aeap.2021.33.4.325.
Colorado among fastest-growing states last decade. United States Census Bureau. 2022. https://www.census.gov/library/stories/state-by-state/colorado-population-change-between-census-decade.html. Accessed 21 Mar 2023.
Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data): National HIV Surveillance System Data Reported through June 2021; and Preexposure Prophylaxis (PrEP) Data Reported through March 2021. Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-4/index.html. Accessed 21 Mar 2023.
Preexposure Prophylaxis for the Prevention of HIV infection in the United States—2021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention. 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed 21 Mar 2023.
Zhao A, Dangerfield DT, Nunn A, et al. Pharmacy–based interventions to increase use of HIV pre–exposure prophylaxis in the United States: a scoping review. AIDS Behav. 2022;26:1377–92. https://doi.org/10.1007/s10461-021-03494-4.
Acknowledgements
none.
Funding
No funding was received for conducting this study.
Author information
Authors and Affiliations
Contributions
All authors contributed to study conception and design. Sarah Billups, Joseph Saseen, and Rhianna Fink served as faculty mentors to Anushka Tandon. Anushka Tandon completed material preparation and data collection. Anushka Tandon and Sarah Billups completed data analysis. Anushka Tandon wrote the first draft of the manuscript; all authors reviewed and contributed to manuscript versions. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors have no relevant financial or non-financial interests to disclose.
Ethics Approval
This research study was conducted retrospectively from data obtained for clinical purposes. We consulted with the Colorado Multiple Institutional Review Board (COMIRB), who determined that our study did not need ethical approval. COMIRB granted an official waiver of ethical approval for our study protocol (COMIRB protocol #21-4707).
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tandon, A., Saseen, J.J., Fink, R.M. et al. Primary Care and Infectious Disease Provider Adherence to HIV Pre-exposure Prophylaxis (PrEP) Prescribing and Monitoring Recommendations. AIDS Behav 28, 1270–1275 (2024). https://doi.org/10.1007/s10461-023-04154-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-023-04154-5